Business Description
BioNTech SE
NAICS : 541714
SIC : 2833
ISIN : US09075V1026
Share Class Description:
BNTX: ADRTotal Employee Number:
7,807Compare
Compare
Traded in other countries / regions
BNTX.USA22UA.Germany0A3M.UKBNTXN.MexicoB1NT34.BrazilBNTX.Austria22UA.Bulgaria IPO Date
2019-10-10Description
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 48.35 | |||||
Equity-to-Asset | 0.89 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.58 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 6.95 | |||||
Beneish M-Score | -3.21 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -42.6 | |||||
3-Year Book Growth Rate | 0.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.86 | |||||
9-Day RSI | 47.84 | |||||
14-Day RSI | 48.77 | |||||
3-1 Month Momentum % | -12.36 | |||||
6-1 Month Momentum % | -17.89 | |||||
12-1 Month Momentum % | -20.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.8 | |||||
Quick Ratio | 8.74 | |||||
Cash Ratio | 8.29 | |||||
Days Inventory | 104.85 | |||||
Days Sales Outstanding | 114.05 | |||||
Days Payable | 268.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | -0.15 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.61 | |||||
Operating Margin % | -27.08 | |||||
Net Margin % | -44.22 | |||||
EBITDA Margin % | -18.26 | |||||
FCF Margin % | 21.84 | |||||
OCF Margin % | 29.28 | |||||
ROE % | -6.74 | |||||
ROA % | -5.9 | |||||
ROIC % | -10.98 | |||||
3-Year ROIIC % | 3827.09 | |||||
ROC (Joel Greenblatt) % | -77.75 | |||||
ROCE % | -5.07 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 9.17 | |||||
PS Ratio | 6.72 | |||||
PB Ratio | 1.07 | |||||
Price-to-Tangible-Book | 1.19 | |||||
Price-to-Free-Cash-Flow | 29.48 | |||||
Price-to-Operating-Cash-Flow | 22.33 | |||||
EV-to-EBIT | -5.77 | |||||
EV-to-Forward-EBIT | -4.87 | |||||
EV-to-EBITDA | -10.94 | |||||
EV-to-Forward-EBITDA | -4.47 | |||||
EV-to-Revenue | 2 | |||||
EV-to-Forward-Revenue | 2.77 | |||||
EV-to-FCF | 9.15 | |||||
Price-to-GF-Value | 1.06 | |||||
Price-to-Projected-FCF | 0.51 | |||||
| Price-to-Net-Current-Asset-Value | 1.52 | |||||
| Price-to-Net-Cash | 1.63 | |||||
Earnings Yield (Greenblatt) % | -17.33 | |||||
FCF Yield % | 3.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BNTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioNTech SE Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,282.614 | ||
| EPS (TTM) ($) | -5.878 | ||
| Beta | 1.3221 | ||
| 3-Year Sharpe Ratio | -0.04 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 36.64 | ||
| 14-Day RSI | 48.77 | ||
| 14-Day ATR ($) | 2.550649 | ||
| 20-Day SMA ($) | 92.21825 | ||
| 12-1 Month Momentum % | -20.44 | ||
| 52-Week Range ($) | 79.52 - 124 | ||
| Shares Outstanding (Mil) | 252.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioNTech SE Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioNTech SE Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 08:00 | In 110 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 109 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 08:00 | In 19 days | ||
| Second quarter earnings results for 2026 | 2026-08-04 | In 18 days | ||
| General meeting for 2026 | 2026-05-15 14:00 | 91.99 (-0.01%) | ||
| First quarter earnings conference call for 2026 | 2026-05-05 08:00 | 99.35 (+0.48%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 99.35 (+0.48%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-10 08:00 | 102.16 (+1.69%) | ||
| Annual report for 2025 | 2026-03-10 | 102.16 (+1.69%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 102.16 (+1.69%) |
Show
Entries
BioNTech SE Frequently Asked Questions
What is BioNTech SE(BNTX)'s stock price today?
The current price of BNTX is $91.48. The 52 week high of BNTX is $124.00 and 52 week low is $79.52.
When is next earnings date of BioNTech SE(BNTX)?
The next earnings date of BioNTech SE(BNTX) is 2026-08-04 Est..
Does BioNTech SE(BNTX) pay dividends? If so, how much?
BioNTech SE(BNTX) does not pay dividend.
Guru Commentaries on NAS:BNTX
No articles.
Press Release
Articles on BioNTech SE
No articles.
Headlines
See More- 1
Jul 16, 2026
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech
Seeking Alpha • 7:09am
Jul 09, 2026
RFK Jr. to create a list of injuries caused by COVID-19 shots
Seeking Alpha • 7:14am
Jul 04, 2026
BioNTech has reportedly contacted buyers over plans to exit German sites
Seeking Alpha • 10:52am
Jun 30, 2026
RFK Jr. ends Emergency Use Authorizations for COVID-19 drugs
Seeking Alpha • 1:30pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers